GMAB - GENMAB A/S

27.66
-1.990   -7.195%

Share volume: 1,980,646
Last Updated: 03-03-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.15%

PREVIOUS CLOSE
CHG
CHG%
$29.65
-1.99
-0.07%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
34%
Profitability 49%
Dept financing 2%
Liquidity 50%
Performance 23%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-6.05%
1 Month
-13.29%
3 Months
-13.62%
6 Months
1.02%
1 Year
18.56%
2 Year
-2.98%
Key data
Stock price
$27.66
P/E Ratio 
0.00
DAY RANGE
$27.22 - $28.17
EPS 
$1.33
52 WEEK RANGE
$17.24 - $35.43
52 WEEK CHANGE
$14.77
MARKET CAP 
18.386 B
YIELD 
N/A
SHARES OUTSTANDING 
661.369 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-07-2025
BETA 
0.33
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,776,007
AVERAGE 30 VOLUME 
$1,695,777
Company detail
CEO: Jan G. J. van de Winkel
Region: US
Website: genmab.com
Employees: 1,660
IPO year: 2009
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases. The company markets DARZALEX, a human monoclonal antibody for the. treatment of patients with multiple myeloma (MM) and ofatumurnab for. multiple sclerosis (CLL) and multiple sclerosis. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers.

Recent news